Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

BeyondSpring Inc. BYSI

Healthcare  —  Biotechnology
0.78 0.05 6.85% as of 25 Sep
Market cap
$29.8M
P/E
0.0×
Revenue Champion (3y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

BeyondSpring Inc. (BYSI) Business Profile

Updated before January 2025

Company Overview

BeyondSpring Inc. (BYSI) is a global biopharmaceutical company dedicated to developing innovative cancer therapies to address unmet medical needs. Founded in 2013 by Dr. Lan Huang, the company is headquartered in New York City, USA. BeyondSpring operates with a mission to improve the lives of cancer patients worldwide by delivering transformative medicines. Dr. Huang, who also serves as the CEO and Chairperson, has been instrumental in steering the company’s strategic direction. The leadership team includes seasoned professionals with extensive experience in oncology, drug development, and commercialization.

BeyondSpring has established itself as a key player in the oncology sector, leveraging its proprietary technology platforms and robust research capabilities. The company is listed on the NASDAQ under the ticker symbol BYSI and has a global presence with operations in the United States and China.

Core Business Segments

BeyondSpring focuses on two primary business segments: oncology therapeutics and drug discovery platforms.

Oncology Therapeutics

The company’s flagship product is Plinabulin, a first-in-class selective immunomodulating microtubule-binding agent (SIMBA). Plinabulin is being developed for multiple indications, including the prevention of chemotherapy-induced neutropenia (CIN) and as an anti-cancer agent in combination therapies. Key highlights of Plinabulin include:

  • Prevention of CIN: Plinabulin has demonstrated efficacy in reducing the incidence of CIN, a common and severe side effect of chemotherapy.
  • Combination Cancer Therapy: Plinabulin is being evaluated in combination with other cancer treatments, such as checkpoint inhibitors, to enhance therapeutic outcomes.

Drug Discovery Platforms

BeyondSpring also invests in innovative drug discovery platforms to expand its pipeline. The company’s proprietary technology enables the identification and development of novel compounds targeting critical pathways in cancer biology. This segment supports the company’s long-term growth by diversifying its product portfolio.

Business Model

BeyondSpring operates on a hybrid business model that integrates drug development, clinical trials, and commercialization. The company generates revenue through licensing agreements, partnerships, and eventual product sales. Key aspects of its business model include:

  • Research and Development (R&D): BeyondSpring allocates significant resources to R&D to advance its pipeline of oncology drugs.
  • Strategic Partnerships: The company collaborates with academic institutions, research organizations, and pharmaceutical companies to accelerate drug development and expand market reach.
  • Global Market Focus: BeyondSpring targets both developed and emerging markets, leveraging its dual presence in the United States and China.

Strategic Direction

BeyondSpring is committed to advancing its pipeline and expanding its market presence. Key strategic priorities include:

  • Regulatory Approvals: The company is focused on securing regulatory approvals for Plinabulin in multiple indications across key markets.
  • Pipeline Expansion: BeyondSpring aims to diversify its portfolio by developing new drug candidates and exploring additional therapeutic areas.
  • Sustainability Goals: The company is dedicated to sustainable practices in drug development and manufacturing, minimizing its environmental footprint.
  • Global Partnerships: BeyondSpring seeks to strengthen its global partnerships to enhance R&D capabilities and commercial success.

Competitive Landscape

BeyondSpring operates in a highly competitive oncology market. Key competitors include:

  • Amgen: Known for its oncology portfolio, including Neulasta, a leading product for CIN prevention.
  • Roche: A global leader in cancer therapies, offering a wide range of targeted treatments.
  • Merck & Co.: A major player in immuno-oncology with its blockbuster drug Keytruda.
  • Smaller Biotech Firms: Companies such as G1 Therapeutics and Fate Therapeutics also compete in niche oncology segments.

BeyondSpring differentiates itself through its innovative approach to drug development and its focus on unmet medical needs.

Risk Factors

Like any biopharmaceutical company, BeyondSpring faces several risks, including:

  • Regulatory Risks: Delays or failures in obtaining regulatory approvals could impact the company’s growth.
  • Market Dependence: Heavy reliance on Plinabulin as its lead product poses a concentration risk.
  • Supply Chain Disruptions: Global supply chain challenges could affect the availability of raw materials and manufacturing processes.
  • Competitive Pressure: Intense competition in the oncology sector may limit market share and pricing power.

Recent Developments

BeyondSpring has made significant progress in recent years. Key developments include:

  • Clinical Trials: Successful completion of Phase 3 trials for Plinabulin in CIN prevention.
  • Regulatory Submissions: Submission of New Drug Applications (NDAs) to regulatory authorities in the US and China.
  • Partnerships: Collaboration with leading research institutions to explore new indications for Plinabulin.
  • COVID-19 Impact: The pandemic posed challenges but also highlighted the importance of resilient supply chains and adaptive strategies.

Investment Considerations

Investors considering BeyondSpring should weigh the following factors:

Strengths

  • Innovative Pipeline: A robust pipeline with a focus on unmet medical needs.
  • Global Presence: Dual operations in the US and China provide access to large markets.
  • Experienced Leadership: A seasoned management team with expertise in oncology and drug development.

Risks

  • Regulatory Uncertainty: Dependence on regulatory approvals for growth.
  • Financial Performance: As a clinical-stage company, BeyondSpring has yet to achieve profitability.
  • Market Competition: Intense competition from established players and emerging biotech firms.

Conclusion

BeyondSpring Inc. is well-positioned in the oncology market with its innovative pipeline and strategic focus on unmet medical needs. While the company faces challenges such as regulatory risks and market competition, its commitment to R&D and global partnerships provides a strong foundation for future growth. Investors should consider BeyondSpring’s potential for long-term value creation as it advances its pipeline and expands its market presence.